Find Research outputs

Search results

• 2020

  Accuracy of noninvasive fibrosis scores to detect advanced fibrosis in patients with type-2 diabetes with biopsy-proven nonalcoholic fatty liver disease

  Singh, A., Gosai, F., Siddiqui, M. T., Gupta, M., Lopez, R., Lawitz, E., Poordad, F., Carey, W., McCullough, A. & Alkhouri, N., Nov 1 2020, In: Journal of Clinical Gastroenterology. 54, 10, p. 891-897 7 p.

  Research output: Contribution to journal › Article › peer-review

  • Non-alcoholic Fatty Liver Disease
  • Type 2 Diabetes Mellitus
  • Fibrosis
  • Biopsy
  • Liver
  3 Scopus citations

• Adherence to pan-genotypic glecaprevir/pibrentasvir and efficacy in HCV-infected patients: A pooled analysis of clinical trials

  Brown, A., Welzel, T. M., Conway, B., Negro, F., Bräu, N., Grebely, J., Puoti, M., Aghemo, A., Kleine, H., Pugatch, D., Mensa, F. J., Chen, Y. J., Lei, Y., Lawitz, E. & Asselah, T., Apr 1 2020, In: Liver International. 40, 4, p. 778-786 9 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • pibrentasvir
  • ABT-493
  • Hepacivirus
  • Clinical Trials
  • Treatment Adherence and Compliance
  4 Scopus citations

• Cilofexor, a Nonsteroidal FXR Agonist, in Patients With Noncirrhotic NASH: A Phase 2 Randomized Controlled Trial

  Patel, K., Harrison, S. A., Elkhashab, M., Trotter, J. F., Herring, R., Rojter, S. E., Kayali, Z., Wong, V. W. S., Greenbloom, S., Jayakumar, S., Shiffman, M. L., Freilich, B., Lawitz, E. J., Gane, E. J., Harting, E., Xu, J., Billin, A. N., Chung, C., Djedjos, C. S., Subramanian, G. M. & 4 others, Myers, R. P., Middleton, M. S., Rinella, M. & Noureddin, M., Jul 1 2020, In: Hepatology. 72, 1, p. 58-71 14 p.

  Research output: Contribution to journal › Article › peer-review

  • Non-alcoholic Fatty Liver Disease
  • Placebos
  • Randomized Controlled Trials
  • Elasticity Imaging Techniques
  • Magnetic Resonance Spectroscopy
  20 Scopus citations

• Effects of Belapectin, an Inhibitor of Galectin-3, in Patients With Nonalcoholic Steatohepatitis With Cirrhosis and Portal Hypertension

  The Belapectin (GR-MD-02) Study Investigators, Apr 2020, In: Gastroenterology. 158, 5, p. 1334-1345.e5

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Galectin 3
  • Portal Hypertension
  • Non-alcoholic Fatty Liver Disease
  • Venous Pressure
  • Fibrosis
  27 Scopus citations

• Efficacy and safety of glecaprevir/pibrentasvir in renally impaired patients with chronic HCV infection

  Lawitz, E., Flisiak, R., Abunimeh, M., Sise, M. E., Park, J. Y., Kaskas, M., Bruchfeld, A., Wörns, M. A., Aglitti, A., Zamor, P. J., Xue, Z., Schnell, G., Jalundhwala, Y. J., Porcalla, A., Mensa, F. J. & Persico, M., May 1 2020, In: Liver International. 40, 5, p. 1032-1041 10 p.

  Research output: Contribution to journal › Article › peer-review

  • pibrentasvir
  • ABT-493
  • Chronic Hepatitis C
  • Hepacivirus
  • Virus Diseases
  7 Scopus citations

• GS-0976 (Firsocostat): an investigational liver-directed acetyl-CoA carboxylase (ACC) inhibitor for the treatment of non-alcoholic steatohepatitis (NASH)

  Alkhouri, N., Lawitz, E., Noureddin, M., DeFronzo, R. & Shulman, G. I., Feb 1 2020, In: Expert Opinion on Investigational Drugs. 29, 2, p. 135-141 7 p.

  Research output: Contribution to journal › Article › peer-review

  • Acetyl-CoA Carboxylase
  • Fatty Liver
  • Malonyl Coenzyme A
  • Lipogenesis
  • Liver
  13 Scopus citations

• Long-term Benefits of Sustained Virologic Response for Patient-Reported Outcomes in Patients With Chronic Hepatitis C Virus Infection

  Younossi, Z. M., Stepanova, M., Racila, A., Afendy, A., Lawitz, E. J., Schwabe, C., Ruane, P. J., Lalezari, J., Reddy, K. R., Jacobson, I. M., Muir, A. J., Gaggar, A., Myers, R. P., Younossi, I. & Nader, F., Feb 2020, In: Clinical Gastroenterology and Hepatology. 18, 2, p. 468-476.e11

  Research output: Contribution to journal › Article › peer-review

  • Sustained Virologic Response
  • Patient Reported Outcome Measures
  • Chronic Hepatitis C
  • Hepacivirus
  • Virus Diseases
  4 Scopus citations

• Not Achieving Sustained Viral Eradication of Hepatitis C Virus after Treatment Leads to Worsening Patient-reported Outcomes

  Younossi, Z. M., Stepanova, M., Jacobson, I., Muir, A. J., Pol, S., Zeuzem, S., Younes, Z., Herring, R., Lawitz, E., Younossi, I. & Racila, A., Feb 3 2020, In: Clinical Infectious Diseases. 70, 4, p. 628-632 5 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Patient Reported Outcome Measures
  • Hepacivirus
  • Quality of Life
  • Sustained Virologic Response
  • Fibrosis
  3 Scopus citations

• Randomized placebo-controlled trial of emricasan for non-alcoholic steatohepatitis-related cirrhosis with severe portal hypertension

  IDN-6556-14 Investigators , May 2020, In: Journal of Hepatology. 72, 5, p. 885-895 11 p.

  Research output: Contribution to journal › Article › peer-review

  • 3-(2-(2-tert-butylphenylaminooxalyl)aminopropionylamino)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid
  • Venous Pressure
  • Portal Hypertension
  • Fatty Liver
  • Fibrosis
  20 Scopus citations

• Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials

  STELLAR-3 and STELLAR-4 Investigators, Jul 2020, In: Journal of Hepatology. 73, 1, p. 26-39 14 p.

  Research output: Contribution to journal › Article › peer-review

  • Fatty Liver
  • Fibrosis
  • Placebos
  • MAP Kinase Kinase Kinase 5
  • Liver
  39 Scopus citations

• Simeprevir, daclatasvir, and sofosbuvir for hepatitis C virus-infected patients: Long-term follow-up results from the open-label, Phase II IMPACT study

  Lawitz, E., Poordad, F., Gutierrez, J. A., Beumont, M., Beets, G., Vandevoorde, A., Remoortere, P. V., Luo, D., Vijgen, L., Eygen, V. V. & Gamil, M., Jun 1 2020, In: Health Science Reports. 3, 2, e145.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Simeprevir
  • BMS-790052
  • Sofosbuvir
  • Hepacivirus
  • Sustained Virologic Response

• Sofosbuvir plus ribavirin and sofosbuvir plus ledipasvir in patients with genotype 1 or 3 hepatitis C virus and severe renal impairment: a multicentre, phase 2b, non-randomised, open-label study

  Lawitz, E., Landis, C. S., Flamm, S. L., Bonacini, M., Ortiz-Lasanta, G., Huang, J., Zhang, J., Kirby, B. J., De-Oertel, S., Hyland, R. H., Osinusi, A. O., Brainard, D. M., Robson, R., Maliakkal, B. J., Gordon, S. C. & Gane, E. J., Oct 2020, In: The Lancet Gastroenterology and Hepatology. 5, 10, p. 918-926 9 p.

  Research output: Contribution to journal › Article › peer-review

  • sofosbuvir drug combination ledipasvir
  • Sofosbuvir
  • Ribavirin
  • Hepacivirus
  • Genotype
  4 Scopus citations

• Variability and lability of ammonia levels in healthy volunteers and patients with cirrhosis: Implications for trial design and clinical practice

  Bajaj, J. S., Bloom, P. P., Chung, R. T., Hassanein, T. I., Padilla-Martinez, M., Kayali, Z., Rockey, D. C., Sasso, R., Muthukumar, A. R., Lee, W. M., Denney, W. S., Gavis, E. A., Anderson, C., Blankstein, L., Brennan, A. M., Puurunen, M. K. & Lawitz, E., 2020, In: American Journal of Gastroenterology. 115, 5, p. 783-785 3 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Ammonia
  • Fibrosis
  • Healthy Volunteers
  • Clinical Trials
  • Hepatic Encephalopathy
  4 Scopus citations
• 2019

  Characteristics and outcomes of liver transplantation for primary biliary cholangitis in young patients: Analysis of the united network for organ sharing database

  Singh, A., Fritze, D., Mansouri, M., Lopez, R., Poordad, F., Lawitz, E., Cigarroa, F., Halff, G. & Alkhouri, N., Jun 1 2019, In: Transplantation. 103, 6, p. 1191-1198 8 p.

  Research output: Contribution to journal › Article › peer-review

  • Cholangitis
  • Liver Transplantation
  • Databases
  • Mechanical Ventilators
  • Mortality
  1 Scopus citations

• Characterization of patients with both alcoholic and nonalcoholic fatty liver disease in a large United States cohort

  Khoudari, G., Singh, A., Noureddin, M., Fritze, D., Lopez, R., Asaad, I., Lawitz, E., Poordad, F., Kowdley, K. V. & Alkhouri, N., 2019, In: World Journal of Hepatology. 11, 10, p. 710-718 9 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Alcoholic Fatty Liver
  • Non-alcoholic Fatty Liver Disease
  • Alcoholics
  • Metabolic Syndrome
  • Alanine Transaminase
  3 Scopus citations

• CONTROL: A randomized phase 2 study of obeticholic acid and atorvastatin on lipoproteins in nonalcoholic steatohepatitis patients

  Pockros, P. J., Fuchs, M., Freilich, B., Schiff, E., Kohli, A., Lawitz, E. J., Hellstern, P. A., Owens-Grillo, J., Van Biene, C., Shringarpure, R., MacConell, L., Shapiro, D. & Cohen, D. E., Nov 1 2019, In: Liver International. 39, 11, p. 2082-2093 12 p.

  Research output: Contribution to journal › Article › peer-review

  • obeticholic acid
  • Atorvastatin
  • Non-alcoholic Fatty Liver Disease
  • Lipoproteins
  • LDL Cholesterol
  25 Scopus citations

• Efficacy and safety of a two-drug direct-acting antiviral agent regimen ruzasvir 180 mg and uprifosbuvir 450 mg for 12 weeks in adults with chronic hepatitis C virus genotype 1, 2, 3, 4, 5 or 6

  the C-BREEZE-2 Study Investigators, 2019, In: Journal of Viral Hepatitis. 26, 9, p. 1127-1138 12 p.

  Research output: Contribution to journal › Article › peer-review

  • ruzasvir
  • uprifosbuvir
  • Chronic Hepatitis C
  • Hepacivirus
  • Antiviral Agents
  3 Scopus citations

• Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir in Patients With Hepatitis C Virus Genotype 1 or 4 Infection and Advanced Kidney Disease

  Lawitz, E., Gane, E., Cohen, E., Vierling, J., Agarwal, K., Hassanein, T., Mantry, P. S., Pockros, P. J., Bennett, M., Kemmer, N., Morelli, G., Zha, J., Wang, D., Shulman, N. S., Cohen, D. E. & Reddy, K. R., Feb 2019, In: Kidney International Reports. 4, 2, p. 257-266 10 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • ABT-267
  • ABT-450
  • Ritonavir
  • Kidney Diseases
  • Hepacivirus
  9 Scopus citations

• Efficacy and safety of ruzasvir 60 mg and uprifosbuvir 450 mg for 12 weeks in adults with chronic hepatitis C virus genotype 1, 2, 3, 4 or 6 infection

  Lawitz, E., Poordad, F., Anderson, L. J., Vesay, M., Kelly, M. M., Liu, H., Gao, W., Fernsler, D., Asante-Appiah, E., Robertson, M. N., Hanna, G. J., Barr, E., Butterton, J., Kowdley, K. V., Hassanein, T., Sahota, A., Gordon, S. C. & Yeh, W. W., Jun 2019, In: Journal of Viral Hepatitis. 26, 6, p. 675-684 10 p.

  Research output: Contribution to journal › Article › peer-review

  • ruzasvir
  • uprifosbuvir
  • Chronic Hepatitis C
  • Hepacivirus
  • Genotype
  2 Scopus citations

• Longitudinal correlations between MRE, MRI-PDFF, and liver histology in patients with non-alcoholic steatohepatitis: Analysis of data from a phase II trial of selonsertib

  Jayakumar, S., Middleton, M. S., Lawitz, E. J., Mantry, P. S., Caldwell, S. H., Arnold, H., Mae Diehl, A., Ghalib, R., Elkhashab, M., Abdelmalek, M. F., Kowdley, K. V., Stephen Djedjos, C., Xu, R., Han, L., Mani Subramanian, G., Myers, R. P., Goodman, Z. D., Afdhal, N. H., Charlton, M. R., Sirlin, C. B. & 1 others, Loomba, R., Jan 2019, In: Journal of Hepatology. 70, 1, p. 133-141 9 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Elasticity Imaging Techniques
  • Fatty Liver
  • Protons
  • Histology
  • Data Analysis
  58 Scopus citations

• Noninvasive Tests Accurately Identify Advanced Fibrosis due to NASH: Baseline Data From the STELLAR Trials

  Anstee, Q. M., Lawitz, E. J., Alkhouri, N., Wong, V. W. S., Romero-Gomez, M., Okanoue, T., Trauner, M., Kersey, K., Li, G., Han, L., Jia, C., Wang, L., Chen, G., Subramanian, G. M., Myers, R. P., Djedjos, C. S., Kohli, A., Bzowej, N., Younes, Z., Sarin, S. & 5 others, Shiffman, M. L., Harrison, S. A., Afdhal, N. H., Goodman, Z. & Younossi, Z. M., Nov 1 2019, In: Hepatology. 70, 5, p. 1521-1530 10 p.

  Research output: Contribution to journal › Article › peer-review

  • Non-alcoholic Fatty Liver Disease
  • Fibrosis
  • Liver Cirrhosis
  • Elasticity Imaging Techniques
  • Vibration
  40 Scopus citations

• Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial

  REGENERATE Study Investigators, Dec 14 2019, In: The Lancet. 394, 10215, p. 2184-2196 13 p.

  Research output: Contribution to journal › Article › peer-review

  • obeticholic acid
  • Fatty Liver
  • Placebos
  • Fibrosis
  • Therapeutics
  159 Scopus citations

• Ombitasvir/paritaprevir/ritonavir + dasabuvir +/- ribavirin in real world hepatitis C patients

  Loo, N., Lawitz, E., Alkhouri, N., Wells, J., Landaverde, C., Coste, A., Salcido, R., Scott, M. & Poordad, F., 2019, In: World Journal of Gastroenterology. 25, 18, p. 2229-2239 11 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • ABT-333
  • ABT-267
  • ABT-450
  • Ritonavir
  • Ribavirin
  1 Scopus citations

• Patients with nonalcoholic steatohepatitis experience severe impairment of health-related quality of life

  Younossi, Z. M., Stepanova, M., Lawitz, E. J., Reddy, K. R., Wong, V. W. S., Mangia, A., Muir, A. J., Jacobson, I., Djedjos, C. S., Gaggar, A., Myers, R. P., Younossi, I., Nader, F. & Racila, A., Oct 2019, In: American Journal of Gastroenterology. 114, 10, p. 1636-1641 6 p.

  Research output: Contribution to journal › Article › peer-review

  • Non-alcoholic Fatty Liver Disease
  • Quality of Life
  • Chronic Hepatitis C
  • Fibrosis
  • Liver Diseases
  3 Scopus citations

• Pharmacokinetics and safety of glecaprevir and pibrentasvir in HCV-negative subjects with hepatic impairment

  Kosloski, M. P., Wang, H., Pugatch, D., Mensa, F. J., Gane, E., Lawitz, E., Marbury, T. C., Preston, R. A., Kort, J. & Liu, W., Feb 6 2019, In: European Journal of Clinical Pharmacology. 75, 2, p. 217-226 10 p.

  Research output: Contribution to journal › Article › peer-review

  • pibrentasvir
  • ABT-493
  • Pharmacokinetics
  • Safety
  • Liver
  3 Scopus citations

• Real-world observational experience with direct-acting antivirals for hepatitis C: baseline resistance, efficacy, and need for long-term surveillance

  Loo, N., Hanysak, B., Mann, J., Ramirez, R., Kim, J., Mitchell, R., Van Frank, T., Guerrero, R., Hinojosa, K., Christensen, K., Pedicone, L. D., Alkhouri, N., Wells, J., Landaverde, C., Rodas, F., Lawitz, E. & Poordad, F., Jun 1 2019, In: Medicine. 98, 26, p. e16254

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Hepatitis C
  • Sustained Virologic Response
  • Antiviral Agents
  • Fibrosis
  • Guidelines
  3 Scopus citations

• Reduced Patient-Reported Outcome Scores Associate With Level of Fibrosis in Patients With Nonalcoholic Steatohepatitis

  Younossi, Z. M., Stepanova, M., Anstee, Q. M., Lawitz, E. J., Wai-Sun Wong, V., Romero-Gomez, M., Kersey, K., Li, G., Subramanian, G. M., Myers, R. P., Djedjos, C. S., Okanoue, T., Trauner, M., Goodman, Z. & Harrison, S. A., Nov 2019, In: Clinical Gastroenterology and Hepatology. 17, 12, p. 2552-2560.e10

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Patient Reported Outcome Measures
  • Non-alcoholic Fatty Liver Disease
  • Fibrosis
  • Comorbidity
  • Clinical Trials
  16 Scopus citations
• 2018

  A 3-year follow-up study after treatment with simeprevir in combination with pegylated interferon-α and ribavirin for chronic hepatitis C virus infection

  Zoulim, F., Moreno, C., Lee, S. S., Buggisch, P., Horban, A., Lawitz, E., Corbett, C., Lenz, O., Fevery, B., Verbinnen, T., Shukla, U. & Jessner, W., Jan 30 2018, In: Virology Journal. 15, 1, 26.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Simeprevir
  • Sustained Virologic Response
  • Ribavirin
  • Chronic Hepatitis C
  • Hepacivirus
  2 Scopus citations

• Acetyl-CoA Carboxylase Inhibitor GS-0976 for 12 Weeks Reduces Hepatic De Novo Lipogenesis and Steatosis in Patients With Nonalcoholic Steatohepatitis

  Lawitz, E. J., Coste, A., Poordad, F., Alkhouri, N., Loo, N., McColgan, B. J., Tarrant, J. M., Nguyen, T., Han, L., Chung, C., Ray, A. S., McHutchison, J. G., Subramanian, G. M., Myers, R. P., Middleton, M. S., Sirlin, C., Loomba, R., Nyangau, E., Fitch, M., Li, K. & 1 others, Hellerstein, M., Dec 2018, In: Clinical Gastroenterology and Hepatology. 16, 12, p. 1983-1991.e3

  Research output: Contribution to journal › Article › peer-review

  • Acetyl-CoA Carboxylase
  • Lipogenesis
  • Non-alcoholic Fatty Liver Disease
  • Liver
  • Elasticity Imaging Techniques
  60 Scopus citations

• Characterization of HCV resistance from a 3-day monotherapy study of voxilaprevir, a novel pangenotypic NS3/4A protease inhibitor

  Lawitz, E., Yang, J. C., Stamm, L. M., Taylor, J. G., Cheng, G., Brainard, D. M., Miller, M. D., Mo, H. & Dvory-Sobol, H., 2018, In: Antiviral Therapy. 23, 4, p. 325-334 10 p.

  Research output: Contribution to journal › Article › peer-review

  • voxilaprevir
  • Protease Inhibitors
  • Viral Load
  • Hepatitis C virus NS3-4A serine protease
  • Genotype
  16 Scopus citations

• Correction: Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein levels predict the presence of fibrotic nonalcoholic steatohepatitis (NASH) and NASH cirrhosis (PLoS ONE (2018) 13:8 (e0202226) DOI: 10.1371/journal.pone.0202226)

  Alkhouri, N., Johnson, C., Adams, L., Kitajima, S., Tsuruno, C., Colpitts, T. L., Hatcho, K., Lawitz, E., Lopez, R. & Feldstein, A. E., Oct 2018, In: PloS one. 13, 10, e0205541.

  Research output: Contribution to journal › Comment/debate › peer-review

  Open Access

  • Wisteria floribunda
  • wisteria lectin
  • Non-alcoholic Fatty Liver Disease
  • agglutinins
  • Names

• DNA methylation signatures reflect aging in patients with nonalcoholic steatohepatitis

  Loomba, R., Gindin, Y., Jiang, Z., Lawitz, E., Caldwell, S., Djedjos, C. S., Xu, R., Chung, C., Myers, R. P., Subramanian, G. M., Goodman, Z., Charlton, M., Afdhal, N. H. & Diehl, A. M., Jan 25 2018, In: JCI Insight. 3, 2

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Non-alcoholic Fatty Liver Disease
  • DNA Methylation
  • Acceleration
  • Collagen
  • Liver
  12 Scopus citations

• Efficacy and safety of 6 or 8 weeks of simeprevir, daclatasvir, sofosbuvir for HCV genotype 1 infection

  Sulkowski, M. S., Feld, J. J., Lawitz, E., Felizarta, F., Corregidor, A. M., Khalid, O., Ghalib, R., Smith, W. B., Van Eygen, V., Luo, D., Vijgen, L., Gamil, M., Kakuda, T. N., Ouwerkerk-Mahadevan, S., Van Remoortere, P. & Beumont, M., Jun 2018, In: Journal of Viral Hepatitis. 25, 6, p. 631-639 9 p.

  Research output: Contribution to journal › Article › peer-review

  • Simeprevir
  • BMS-790052
  • Sofosbuvir
  • Hepacivirus
  • Fibrosis
  8 Scopus citations

• Glecaprevir + pibrentasvir (ABT493 + ABT-530) for the treatment of Hepatitis C

  Hubbard, H. & Lawitz, E., Jan 2 2018, In: Expert Review of Gastroenterology and Hepatology. 12, 1, p. 9-17 9 p.

  Research output: Contribution to journal › Article › peer-review

  • ABT-530
  • pibrentasvir
  • ABT-493
  • Hepatitis C
  • Antiviral Agents
  17 Scopus citations

• GS-0976 Reduces Hepatic Steatosis and Fibrosis Markers in Patients With Nonalcoholic Fatty Liver Disease

  Loomba, R., Kayali, Z., Noureddin, M., Ruane, P., Lawitz, E. J., Bennett, M., Wang, L., Harting, E., Tarrant, J. M., McColgan, B. J., Chung, C., Ray, A. S., Subramanian, G. M., Myers, R. P., Middleton, M. S., Lai, M., Charlton, M. & Harrison, S. A., Nov 2018, In: Gastroenterology. 155, 5, p. 1463-1473.e6

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Non-alcoholic Fatty Liver Disease
  • Fibrosis
  • Liver
  • Placebos
  • Protons
  81 Scopus citations

• Improvement of hepatic fibrosis and patient-reported outcomes in non-alcoholic steatohepatitis treated with selonsertib

  Younossi, Z. M., Stepanova, M., Lawitz, E., Charlton, M., Loomba, R., Myers, R. P., Subramanian, M., McHutchison, J. G. & Goodman, Z., Oct 2018, In: Liver International. 38, 10, p. 1849-1859 11 p.

  Research output: Contribution to journal › Article › peer-review

  • Patient Reported Outcome Measures
  • Fatty Liver
  • Fibrosis
  • Liver
  • simtuzumab
  22 Scopus citations

• Long-term follow-up of clinical trial patients treated for chronic HCV infection with daclatasvir-based regimens

  Reddy, K. R., Pol, S., Thuluvath, P. J., Kumada, H., Toyota, J., Chayama, K., Levin, J., Lawitz, E. J., Gadano, A., Ghesquiere, W., Gerken, G., Brunetto, M. R., Peng, C. Y., Silva, M., Strasser, S. I., Heo, J., McPhee, F., Liu, Z., Yang, R., Linaberry, M. & 1 others, Noviello, S., May 2018, In: Liver International. 38, 5, p. 821-833 13 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • BMS-790052
  • Chronic Hepatitis C
  • Sustained Virologic Response
  • Hepacivirus
  • Virus Diseases
  14 Scopus citations

• Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial

  Sanyal, A., Charles, E. D., Neuschwander-Tetri, B. A., Loomba, R., Harrison, S. A., Abdelmalek, M. F., Lawitz, E. J., Halegoua-DeMarzio, D., Kundu, S., Noviello, S., Luo, Y. & Christian, R., Dec 22 2018, In: The Lancet. 392, 10165, p. 2705-2717 13 p.

  Research output: Contribution to journal › Article › peer-review

  • fibroblast growth factor 21
  • Fatty Liver
  • Placebos
  • Fats
  • Liver
  117 Scopus citations

• Pharmacokinetics and Safety of Velpatasvir and Sofosbuvir/Velpatasvir in Subjects with Hepatic Impairment

  Mogalian, E., Brainard, D. M., Osinusi, A., Moorehead, L., Murray, B., Ling, K. H. J., Perry, R., Curtis, C., Lawitz, E., Lasseter, K., Marbury, T. & Mathias, A., Nov 1 2018, In: Clinical Pharmacokinetics. 57, 11, p. 1449-1457 9 p.

  Research output: Contribution to journal › Article › peer-review

  • velpatasvir
  • Sofosbuvir
  • Pharmacokinetics
  • Safety
  • Liver
  6 Scopus citations

• Resistance analysis of a 3-day monotherapy study with glecaprevir or pibrentasvir in patients with chronic hepatitis C virus genotype 1 infection

  Ng, T. I., Pilot-Matias, T., Tripathi, R., Schnell, G., Krishnan, P., Reisch, T., Beyer, J., Dekhtyar, T., Irvin, M., Lu, L., Asatryan, A., Campbell, A., Yao, B., Lovell, S., Mensa, F., Lawitz, E. J., Kort, J. & Collins, C., Sep 2018, In: Viruses. 10, 9, 462.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • pibrentasvir
  • ABT-493
  • Chronic Hepatitis C
  • Hepacivirus
  • Genotype
  2 Scopus citations

• Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein levels predict the presence of fibrotic nonalcoholic steatohepatitis (NASH) and NASH cirrhosis

  Alkhouri, N., Johnson, C., Adams, L., Kitajima, S., Tsuruno, C., Colpitts, T. L., Hatcho, K., Lawitz, E., Lopez, R. & Feldstein, A., Aug 2018, In: PloS one. 13, 8, e0202226.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Wisteria floribunda
  • wisteria lectin
  • fatty liver
  • Non-alcoholic Fatty Liver Disease
  • agglutinins
  6 Scopus citations

• Simtuzumab Is Ineffective for Patients With Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic Steatohepatitis

  GS-US-321-0105 and GS-US-321-0106 Investigators, Oct 2018, In: Gastroenterology. 155, 4, p. 1140-1153 14 p.

  Research output: Contribution to journal › Article › peer-review

  • simtuzumab
  • Non-alcoholic Fatty Liver Disease
  • Fibrosis
  • Venous Pressure
  • Liver
  82 Scopus citations

• Sofosbuvir and velpatasvir with or without voxilaprevir in direct-acting antiviral-naïve chronic hepatitis C: patient-reported outcomes from POLARIS 2 and 3

  Younossi, Z. M., Stepanova, M., Jacobson, I. M., Asselah, T., Gane, E. J., Lawitz, E., Foster, G. R., Roberts, S. K., Thompson, A. J., Willems, B. E., Welzel, T. M., Pearlman, B., Younossi, I., Racila, A. & Henry, L., Jan 2018, In: Alimentary Pharmacology and Therapeutics. 47, 2, p. 259-267 9 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • voxilaprevir
  • velpatasvir
  • Sofosbuvir
  • Patient Reported Outcome Measures
  • Chronic Hepatitis C
  26 Scopus citations

• The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial

  for the GS-US-384-1497 Investigators, Feb 1 2018, In: Hepatology. 67, 2, p. 549-559 11 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • simtuzumab
  • Non-alcoholic Fatty Liver Disease
  • Fibrosis
  • Elasticity Imaging Techniques
  • Liver
  203 Scopus citations

• The Safety and Antiviral Activity of BZF961 with or without Ritonavir in Patients Infected with Hepatitis C Virus: A Randomized, Multicenter Trial

  Lawitz, E., Bidair, M., Marbury, T., Jones, C. T., Barve, A., Magnusson, B., Barkan, D. T., Bodendorf, U., Bracken, K., Canino, E., Chen, D., Dabovic, K., Heimbach, T., Ison, M., Jones, C. L., Kovacs, S. J., Lakshman, J. P., Li, B., Raman, P., Steiner-Swiat, R. & 4 others, Thohan, S., Wong, K. A., Zhong, W. & Colvin, R. A., Sep 2018, In: Clinical Therapeutics. 40, 9, p. 1567-1581.e4

  Research output: Contribution to journal › Article › peer-review

  • Ritonavir
  • Hepacivirus
  • Multicenter Studies
  • Antiviral Agents
  • Safety
• 2017

  Antiviral response and resistance analysis of treatment-naïve HCV infected patients receiving multiple doses of the NS3 protease inhibitor GS-9256

  Mo, H., Hedskog, C., Lawitz, E., Brainard, D. M., Yang, J., Delaney, W., Worth, A. & Miller, M. D., Apr 1 2017, In: Antiviral Research. 140, p. 151-157 7 p.

  Research output: Contribution to journal › Article › peer-review

  • GS-9256
  • Protease Inhibitors
  • Hepacivirus
  • Antiviral Agents
  • Therapeutics
  3 Scopus citations

• Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials

  Jacobson, I. M., Lawitz, E., Gane, E. J., Willems, B. E., Ruane, P. J., Nahass, R. G., Borgia, S. M., Shafran, S. D., Workowski, K. A., Pearlman, B., Hyland, R. H., Stamm, L. M., Svarovskaia, E., Dvory-Sobol, H., Zhu, Y., Subramanian, G. M., Brainard, D. M., McHutchison, J. G., Bräu, N., Berg, T. & 10 others, Agarwal, K., Bhandari, B. R., Davis, M., Feld, J. J., Dore, G. J., Stedman, C. A. M., Thompson, A. J., Asselah, T., Roberts, S. K. & Foster, G. R., Jul 2017, In: Gastroenterology. 153, 1, p. 113-122 10 p.

  Research output: Contribution to journal › Article › peer-review

  • voxilaprevir
  • velpatasvir
  • Sofosbuvir
  • Chronic Hepatitis C
  • Hepacivirus
  144 Scopus citations

• Glecaprevir and pibrentasvir in patients with HCV and severe renal impairment

  Gane, E., Lawitz, E., Pugatch, D., Papatheodoridis, G., Bräu, N., Brown, A., Pol, S., Leroy, V., Persico, M., Moreno, C., Colombo, M., Yoshida, E. M., Nelson, D. R., Collins, C., Lei, Y., Kosloski, M. & Mensa, F. J., Oct 12 2017, In: New England Journal of Medicine. 377, 15, p. 1448-1455 8 p.

  Research output: Contribution to journal › Article › peer-review

  • pibrentasvir
  • ABT-493
  • Hepacivirus
  • Kidney
  • Chronic Renal Insufficiency
  213 Scopus citations

• Novel treatments for chronic hepatitis C: closing the remaining gaps

  Alkhouri, N., Lawitz, E. & Poordad, F., Dec 2017, In: Current Opinion in Pharmacology. 37, p. 107-111 5 p.

  Research output: Contribution to journal › Review article › peer-review

  • Chronic Hepatitis C
  • Antiviral Agents
  • Hepacivirus
  • Patient Safety
  • Chronic Renal Insufficiency
  14 Scopus citations

• Post-treatment resistance analysis of hepatitis C virus from phase II and III clinical trials of ledipasvir/sofosbuvir

  Wyles, D., Dvory-Sobol, H., Svarovskaia, E. S., Doehle, B. P., Martin, R., Afdhal, N. H., Kowdley, K. V., Lawitz, E., Brainard, D. M., Miller, M. D., Mo, H. & Gane, E. J., Apr 1 2017, In: Journal of Hepatology. 66, 4, p. 703-710 8 p.

  Research output: Contribution to journal › Article › peer-review

  • sofosbuvir drug combination ledipasvir
  • Phase II Clinical Trials
  • Phase III Clinical Trials
  • Hepacivirus
  • ledipasvir
  58 Scopus citations